Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxycodone
Drug ID BADD_D01645
Description Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917.[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Indications and Usage Oxycodone is indicated for the treatment of moderate to severe pain.[Label] There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label]
Marketing Status approved; illicit; investigational
ATC Code N02AA05
DrugBank ID DB00497
KEGG ID D05312
MeSH ID D010098
PubChem ID 5284603
TTD Drug ID D07WPQ
NDC Product Code 71335-0981; 67651-0304; 67651-0305; 67651-0306; 24510-140; 71335-1080; 0904-6966; 24510-130; 65162-048; 67877-625; 71335-0677; 65162-050; 0904-7180; 65162-047; 72162-1812; 67877-623; 67651-0302; 65162-049; 67651-0303; 65162-051; 24510-110; 24510-115; 71335-1023; 24510-120; 72162-1811
UNII CD35PMG570
Synonyms Oxycodone | Dihydrone | Oxycone | Dihydrohydroxycodeinone | Oxycodeinon | Eucodal | Theocodin | Oxycodone Hydrochloride | Oxycontin | Pancodine | Dinarkon | Oxiconum
Chemical Information
Molecular Formula C18H21NO4
CAS Registry Number 76-42-6
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Feelings of worthlessness19.15.02.008--Not Available
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Folate deficiency14.12.02.0060.000021%Not Available
Formication19.10.04.002; 17.02.06.0180.000137%Not Available
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.002--
Gallbladder cancer09.04.02.005; 16.07.05.0010.000021%Not Available
Gamma-glutamyltransferase increased13.03.04.024--
Gastric atony07.02.02.009--Not Available
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.004--
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
Gingivitis07.09.10.002; 11.01.04.013--
Glossitis07.14.01.001--Not Available
Glossodynia07.14.02.001--Not Available
Gout15.01.06.001; 14.09.01.001--Not Available
Gouty arthritis14.09.01.004; 15.01.06.0040.000021%Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Hallucination19.10.04.003--
Hallucination, visual19.10.04.007--Not Available
Head injury12.01.09.003--Not Available
Headache17.14.01.001--
Heart rate increased13.14.04.002--Not Available
Hepatitis09.01.07.004--Not Available
Hepatomegaly09.01.05.001--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 16 Pages